Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New programs aim to help seniors kick the sleeping pill habit

NCT ID NCT03687086

Symptom relief Sponsor: University of California, Los Angeles Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two programs to help older adults stop taking sleeping pills like lorazepam or zolpidem. One program focused on placebo effects—the power of believing a treatment works—while the other did not. Both included cognitive behavioral therapy and special pill packaging. The goal was to see which program helped more people quit sleeping pills safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cognitive behavioral therapy
What this could lead to
If successful, this could provide a better way to help older adults stop taking sleeping pills, reducing health risks.
What could go wrong
This is a completed study, but results may not apply to everyone. The programs require weekly sessions, which may not be practical for all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

188 people

The number who actually took part.

Started

Dec 2018

Finished

Nov 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>= 55 years * Use of lorazepam, alprazolam, temazepam,and/or zolpidem for current or prior insomnia symptoms 2 or more nights per week for at least 3 months * Current or prior insomnia symptoms * Available to attend weekly in-person sessions over 9 weeks Exclusion Criteria: High risk for complications in outpatient hypnotic discontinuation program: * Seizure disorder * Supratherapeutic or high baseline hypnotic dose (\> diazepam-equivalent of 8 mg/night). * High baseline risk of complicated withdrawal;benzodiazepine intoxication or current or past symptoms of complicated benzodiazepine/alcohol withdrawal (e.g.,seizure, delirium at baseline (prior to taper)) * Polydrug use (e.g., chronic high dose opioids) * Unable to keep study medications in secure location * Evidence of prescription fraud (e.g., multiple prescriptions for same drug filled at multiple pharmacies during overlapping time periods, diversion) Discontinuation of hypnotic not appropriate: •Study-targeted hypnotic used to treat another clinical condition (e.g., panic disorder) Poor candidate for cognitive behavioral therapy for insomnia: * Presence of bipolar disorder * Cognitive impairment (e.g., Mini-Mental State Examination \< 24) * Sleep/wake difficulty is better explained by another sleep disorder such as restless legs syndrome, narcolepsy, insufficient sleep syndrome, or circadian rhythm sleep-wake disorders * Untreated sleep-disordered breathing (respiratory event index \>= 15 and \< 30 plus excessive daytime sleepiness, or REI \>=30) * Medically/psychiatrically unstable (e.g., planned major surgery during the study period;psychosis, suicidal, active alcohol/substance abuse based on history and medical records) * Unstable housing situation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sleep initiation and maintenance disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

insomnia sleep disorder, initiating and maintaining sleep

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sleep initiation and maintenance disorders

Contacts and locations

Locations

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • VA Greater Los Angeles

    Los Angeles, California, 90073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.